Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941747 | 0.83 | ALOX5 (0.53) | ALOX5EPHX2 | |
| SCHEMBL8609779 | 0.83 | ALOX5 (0.53) | ALOX5EPHX2 | |
| SCHEMBL9046903 | 0.76 | ALOX5 (0.74) | ALOX5EPHX2 | |
| SCHEMBL8941404 | 0.75 | ALOX5 (0.54) | ALOX5EPHX2 | |
| SCHEMBL8941581 | 0.75 | PPARG (0.49) | ALOX5EPHX2 | |
| SCHEMBL9048674 | 0.74 | ALOX5 (0.71) | ALOX5EPHX2 | |
| SCHEMBL8941419 | 0.73 | ALOX5 (0.63) | ALOX5EPHX2 | |
| SCHEMBL9046513 | 0.73 | ALOX5 (0.60) | ALOX5EPHX2 | |
| SCHEMBL8965068 | 0.72 | ALOX5 (0.61) | ALOX5EPHX2 | |
| SCHEMBL8305352 | 0.72 | ALOX5 (0.68) | ALOX5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832078-B1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1999-10-20 | — | — | EP | claimed |
| US-5814648-A | N-hydroxyureas as antiinflammatory agents | PFIZER INC. (US) | 1998-09-29 | — | — | US | claimed |
| EP-0832078-A1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040659-A1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0832078-B1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5814648-A | N-hydroxyureas as antiinflammatory agents | PFIZER INC. (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0832078-A1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040659-A1 | N-HYDROXYUREAS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | ALOX5 1721/4885EPHX2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.